Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG-BM1 allogeneic bone marrow mesenchymal stem cell injection for HBV-related acute-on-chronic liver failure
CTR20243643Phase 2Active
- Sponsor
- Saijun Biotech
- Start
- Aug 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CG-BM1 in acute-on-chronic liver failure (ACLF), sponsored by Saijun Biotech. Started Aug 2024; status: active.
02
Drugs
CG-BM1
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on CTR20243643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243643.